ENTA stock forecast, quote, news & analysis
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications... Show more
Why Enanta Pharmaceuticals (ENTA) Stock Is Down -10.6% in the Last 30 Days
Key Takeaways
- Enanta Pharmaceuticals (ENTA) shares fell approximately 10.6% over the last 30 days, declining from $14.00 to $12.52, driven primarily by dilution concerns following a $75 million at-the-market (ATM) equity offering announced on July 2, 2026.
- Over the broader quarter, ENTA declined roughly 9.9% from $13.89 in late April to current levels, reflecting sustained pressure from cash-burn dynamics and uncertainty around the ATM facility's utilization.
- The June 2026 advancement of the zelicapavir RSV program following a successful End-of-Phase 2 FDA meeting provided a notable positive catalyst but was overshadowed by financing-related headwinds.
- Analyst consensus remains "Moderate Buy" with an average price target of approximately $20.29, though one firm maintains a Sell rating, highlighting a divided sentiment on ENTA's risk-reward profile.
- Upcoming catalysts include the initiation of a registrational Phase 2b/3 trial for zelicapavir in high-risk adults in Q4 2026 and topline Phase 1 data for EDP-978, the oral KIT inhibitor, expected by year-end.
Enanta Pharmaceuticals (ENTA) Company Overview and Market Position
Enanta Pharmaceuticals is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, focused on discovering and developing small-molecule drugs for virology and immunology indications. The company is best known for discovering glecaprevir, a protease inhibitor that forms a key component of AbbVie's blockbuster hepatitis C treatment MAVYRET/MAVIRET, which generates royalty revenue for Enanta. The company's current pipeline is anchored by zelicapavir, an oral, once-daily N-protein inhibitor targeting respiratory syncytial virus (RSV), which has received Fast Track designation from the FDA. Enanta is also advancing EDP-323, an L-protein inhibitor for RSV, and EDP-978, an oral KIT inhibitor targeting chronic urticaria in immunology. With a market capitalization of approximately $370 million and no approved in-house products generating direct revenue, Enanta remains a high-risk, high-reward biotech primarily valued on pipeline execution and partnership potential.
Enanta Pharmaceuticals (ENTA) Stock Price Performance: Last 30 Days vs. Quarter
ENTA stock closed at $14.00 on June 26, 2026, and has since declined to $12.52 as of the latest available data on July 28, representing a drop of approximately 10.6% over the 30-day window. The stock initially showed strength entering July, reaching $15.11 on July 2, before the ATM offering announcement triggered a sharp reversal. Over the broader quarter, ENTA declined roughly 9.9% from $13.89 at the end of April, showing a gradual erosion of value punctuated by brief rallies around pipeline updates. The 50-day moving average sits near $13.46, while the 200-day moving average is around $13.64, both above the current trading level, indicating bearish short- to medium-term technical pressure. Trading volume spiked notably on June 26, exceeding 938,000 shares, coinciding with heightened attention around RSV program developments.
What Drove ENTA Stock Price in the Last 30 Days
The dominant catalyst behind ENTA's 30-day decline was the July 2, 2026 announcement of a $75 million at-the-market equity offering agreement with Jefferies LLC. While ATM facilities are common among clinical-stage biotechnology companies as flexible financing tools, the announcement raised concerns among investors about potential dilution of existing shareholders and signaled that Enanta may need additional capital to fund its expanding pipeline. The stock fell from $15.11 on July 2 to below the $13.00 level within two weeks, as selling pressure persisted. On the positive side, Enanta's June 18 announcement regarding the advancement of the zelicapavir clinical development program—following a successful End-of-Phase 2 meeting with the FDA and outlining plans for a registrational Phase 2b/3 trial in high-risk adults—provided temporary support. The company also benefits from a generally favorable analyst backdrop, with seven of eight covering analysts maintaining Buy ratings and an average price target above $20, though Weiss Ratings reiterated a "Sell (D-)" rating, creating a mixed sentiment environment. The broader biotechnology sector also faced headwinds, compounding ENTA's specific challenges.
What Drove ENTA Stock Performance Over the Last Quarter
ENTA's quarterly performance reflects a biotech caught between promising pipeline progress and persistent financial overhang. The period opened with the company's fiscal Q2 2026 earnings report on May 11, which showed a narrower-than-expected loss of -$0.45 per share versus consensus estimates of -$0.46, along with revenue of $17.16 million slightly ahead of forecasts. Positive clinical momentum continued through the quarter with data presentations at major medical conferences including the American Thoracic Society International Conference and ESCMID Global 2026. The zelicapavir program's advancement in June marked a significant de-risking event, confirming FDA alignment on the registrational path. However, the company's pre-revenue status and negative cash flow remain fundamental headwinds. The ATM facility announcement crystallized investor concerns about the company's cash runway despite its strong institutional ownership at nearly 95%. The net result was a gradual decline punctuated by brief optimism around clinical updates, ultimately leaving the stock lower across the quarter.
Trending AI Robots
For investors seeking data-driven approaches to navigate volatile biotechnology stocks like ENTA, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that trade thousands of tickers across diverse strategies, timeframes, and performance metrics, but only the top-performing and most relevant bots are featured in this section. These bots leverage technical analysis, pattern recognition, and algorithmic signals to identify potential opportunities in real time, providing traders with actionable insights without requiring constant manual monitoring. Each bot varies in its approach—some focus on short-term momentum, others on swing trading or longer-term trends—allowing users to match strategies to their individual risk profiles and goals.
ENTA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several key factors will shape ENTA's trajectory. The initiation of the registrational Phase 2b/3 trial for zelicapavir in high-risk adults, expected in Q4 2026, represents the single most important near-term catalyst, as this trial will ultimately determine the drug's path toward potential FDA approval. Additionally, topline Phase 1 data for EDP-978, the oral KIT inhibitor, is expected in Q4 2026 and could validate Enanta's expansion into immunology. On the financial front, investors should monitor whether and to what extent Enanta draws on the $75 million ATM facility, as any substantial utilization could apply further dilution pressure. The upcoming fiscal Q3 2026 earnings report, expected around August 10, will provide updated cash runway guidance and pipeline timelines. Macroeconomic factors, including interest rate expectations affecting the biotechnology funding environment, also warrant attention. Competitive dynamics in the RSV space remain important, as other players continue advancing antiviral and vaccine programs targeting the same patient populations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ENTA in +3.64% Uptrend, advancing for three consecutive days on July 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ENTA advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In of 182 cases where ENTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ENTA moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTA as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ENTA turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
ENTA moved below its 50-day moving average on July 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENTA crossed bearishly below the 50-day moving average on July 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for ENTA moved below the 200-day moving average on July 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ENTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.133) is normal, around the industry mean (19.732). P/E Ratio (0.000) is within average values for comparable stocks, (38.804). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.750). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (4.562) is also within normal values, averaging (423.664).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs and other pharmaceuticals products
Industry Biotechnology